ATE352312T1 - Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors - Google Patents

Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors

Info

Publication number
ATE352312T1
ATE352312T1 AT02787467T AT02787467T ATE352312T1 AT E352312 T1 ATE352312 T1 AT E352312T1 AT 02787467 T AT02787467 T AT 02787467T AT 02787467 T AT02787467 T AT 02787467T AT E352312 T1 ATE352312 T1 AT E352312T1
Authority
AT
Austria
Prior art keywords
glp
compound
combined use
reductase inhibitor
aldose reductase
Prior art date
Application number
AT02787467T
Other languages
English (en)
Inventor
Lotte Bjerre Knudsen
Johan Selmer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE352312T1 publication Critical patent/ATE352312T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT02787467T 2001-12-29 2002-12-20 Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors ATE352312T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101969 2001-12-29
DKPA200200760 2002-05-17

Publications (1)

Publication Number Publication Date
ATE352312T1 true ATE352312T1 (de) 2007-02-15

Family

ID=26069120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787467T ATE352312T1 (de) 2001-12-29 2002-12-20 Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors

Country Status (8)

Country Link
US (3) US20030144206A1 (de)
EP (2) EP1790353A1 (de)
JP (1) JP2005516968A (de)
AT (1) ATE352312T1 (de)
AU (1) AU2002351753A1 (de)
DE (1) DE60217918T2 (de)
ES (1) ES2280596T3 (de)
WO (1) WO2003059372A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005016911A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
EP1581246B1 (de) 2003-12-17 2013-01-16 Amylin Pharmaceuticals, LLC Zusammensetzungen zur behandlung und prevention von nephropathie
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102127053A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
EP1750862B1 (de) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Irbesartan enthaltende pharmazeutische zusammensetzung
EP1753730A1 (de) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidylpeptidasehemmer
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
EP2805953B1 (de) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl-Peptidase-Hemmer
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US8277415B2 (en) 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8840586B2 (en) 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US8137314B2 (en) 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
US7686787B2 (en) 2005-05-06 2010-03-30 Medtronic Minimed, Inc. Infusion device and method with disposable portion
US20080097291A1 (en) 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
US7905868B2 (en) 2006-08-23 2011-03-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8512288B2 (en) 2006-08-23 2013-08-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1767545B1 (de) 2005-09-22 2009-11-11 Biocompatibles UK Limited Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
US8852164B2 (en) 2006-02-09 2014-10-07 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
EP2338547B1 (de) 2006-02-09 2013-04-17 DEKA Products Limited Partnership Fluidzufuhrsysteme
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ATE444741T1 (de) * 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
US7828764B2 (en) 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7794434B2 (en) 2006-08-23 2010-09-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7811262B2 (en) 2006-08-23 2010-10-12 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7789857B2 (en) 2006-08-23 2010-09-07 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR20150032590A (ko) * 2006-09-13 2015-03-26 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN104189906A (zh) * 2007-01-29 2014-12-10 V生命科学技术有限公司 用于治疗糖尿病并发症的药用组合物
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
US8613725B2 (en) 2007-04-30 2013-12-24 Medtronic Minimed, Inc. Reservoir systems and methods
US8597243B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US7959715B2 (en) 2007-04-30 2011-06-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
US8323250B2 (en) 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
CA2685474C (en) 2007-04-30 2014-07-08 Medtronic Minimed, Inc. Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
US8434528B2 (en) 2007-04-30 2013-05-07 Medtronic Minimed, Inc. Systems and methods for reservoir filling
US10188787B2 (en) 2007-12-31 2019-01-29 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US8414563B2 (en) 2007-12-31 2013-04-09 Deka Products Limited Partnership Pump assembly with switch
US8900188B2 (en) 2007-12-31 2014-12-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US8881774B2 (en) 2007-12-31 2014-11-11 Deka Research & Development Corp. Apparatus, system and method for fluid delivery
US9456955B2 (en) 2007-12-31 2016-10-04 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US10080704B2 (en) 2007-12-31 2018-09-25 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
MX338464B (es) 2007-12-31 2016-04-15 Deka Products Lp Ensamble de bomba de infusion.
EP2163243A1 (de) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
CA2738389C (en) 2008-09-15 2017-01-17 Deka Products Limited Partnership Systems and methods for fluid delivery
EP2251028A1 (de) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Behandlung von Augenerkrankungen unter Verwendung eingekapselter Zellen, die einen antiangiogenetischen Faktor und/oder einen neuroprotektiven Faktor codieren und sekretieren
WO2011008966A2 (en) 2009-07-15 2011-01-20 Deka Products Limited Partnership Apparatus, systems and methods for an infusion pump assembly
WO2013134519A2 (en) 2012-03-07 2013-09-12 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
EP4309699A3 (de) 2013-07-03 2024-04-24 DEKA Products Limited Partnership Vorrichtung und system zur flüssigkeitsabgabe
US11523972B2 (en) 2018-04-24 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264586B1 (de) * 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin-Derivate zur Behandlung von Komplikationen bei Diabetes
BR9404831A (pt) * 1993-12-07 1995-08-08 Lilly Co Eli Composto,formulação farmacêutica e processo de preparação de um composto
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
PL344002A1 (en) * 1998-05-11 2001-09-10 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
AU4394799A (en) * 1998-07-01 2000-01-24 Takeda Chemical Industries Ltd. Retinoid-associated receptor regulators
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
CN1348555A (zh) * 1999-06-29 2002-05-08 精工电子有限公司 具有轮系工作控制机构的机械时计
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
AU1269501A (en) * 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
WO2001066135A1 (en) * 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
HU229208B1 (en) * 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
HUP0401998A2 (hu) * 2001-11-02 2005-01-28 Pfizer Products Inc., PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető

Also Published As

Publication number Publication date
EP1461070B1 (de) 2007-01-24
US20100184690A1 (en) 2010-07-22
US20030144206A1 (en) 2003-07-31
DE60217918D1 (de) 2007-03-15
AU2002351753A1 (en) 2003-07-30
AU2002351753A8 (en) 2003-07-30
WO2003059372A3 (en) 2004-03-25
EP1790353A1 (de) 2007-05-30
ES2280596T3 (es) 2007-09-16
WO2003059372A2 (en) 2003-07-24
DE60217918T2 (de) 2007-11-15
EP1461070A2 (de) 2004-09-29
US20070167373A1 (en) 2007-07-19
JP2005516968A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
ATE352312T1 (de) Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
PT1296959E (pt) Metodos e composicoes que utilizam quinazolinonas
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
DE59910084D1 (de) Organische Salze von Isoleucyl-Thiazolidin und -Pyrrolidin und ihre Verwendung als Dipeptidylpeptidase-Inhibitoren
NO20052139L (no) Bandasje og epidermal posisjoneringsmekanisme og fremgangsmate for anvendelse av samme
ATE381539T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
NO20026038D0 (no) Kombinasjoner av dipeptidylpeptidase IV inhibitorer og andre antidiabetiskemidler for behandlingen av diabetes mellitus
SE0301888D0 (sv) New use VII
WO2002072545A3 (en) 9-aminoacyl tetracycline compounds and methods of use thereof
ATE318139T1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
SE0301886D0 (sv) New use V
TR200100773T2 (tr) Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
MXPA02012713A (es) Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.
NO20071098L (no) Quinazolinderivater som er nyttige ved behandling av perifer arteriesykdom og som fosfodiesterase-inhibitorer
WO2006002763A3 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
PT1378246E (pt) Inibidores da spla2 para a arteriosclerose
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
DE60204611D1 (de) Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
WO2001087281A3 (en) Method for enhancing cognitive function
SE0301883D0 (sv) New use II
AU2003239025A1 (en) Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd
DK17984A (da) Aldosereduktasehaemmende 5-(2-alkoxyphenyl)thiazolidindioner
AU2003221350A1 (en) Light amplifying device and method of manufacturing the device, light source device using the light amplifying device, light treatment device using the light source device, and exposure device using the light source device
UY27145A1 (es) Uso de 2-amino-1-(4-hidroxi-2-metanosulfonamidofenil) etanol para tratar la incontinencia urinaria

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties